Regeneron Pharmaceuticals, Inc. (REGN)

883,20 -7,48 (-0,84%) Al cierre: 04:00PM EDT

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
https://www.regeneron.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 13.450

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Leonard S. Schleifer M.D., Ph.D.	Co-Founder, President, CEO & Co-Chairman	8,18M	N/A	1953
Dr. George D. Yancopoulos M.D., Ph.D.	Co-Founder, President, Chief Scientific Officer & Co-Chairman	7,76M	N/A	1960
Dr. Andrew J. Murphy Ph.D.	Executive Vice President of Research	1,68M	21,37M	1959
Mr. Daniel P. Van Plew	Executive VP and GM of Industrial Operations & Product Supply	2,01M	10,67M	1973
Mr. Christopher R. Fenimore CPA	Senior VP of Finance & CFO	N/A	N/A	1971
Ms. Patrice Gilooly	Senior Vice President of Quality Assurance & Operations	N/A	N/A	N/A
Mr. Bob McCowan	Senior VP of IT & Chief Information Officer	N/A	N/A	N/A
Mr. Ryan Crowe	Senior Vice President of Investor Relations & Strategic Analysis	N/A	N/A	N/A
Mr. Joseph J. LaRosa	Executive VP, General Counsel & Secretary	1,75M	23,23M	1959
Ms. Melissa Lozner	Senior VP & Chief Compliance Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Gobierno corporativo

El ISS Governance QualityScore de Regeneron Pharmaceuticals, Inc., a día 1 de abril de 2024, es 10. Las puntuaciones base son Auditoría: 9; Tablero: 10; Derechos de los accionistas: 10; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.